Introduction: With Neisseria gonorrhoeae rapidly developing resistance to current therapies, the need for effective oral alternatives is urgent. The standard first-line treatment, intramuscular ceftriaxone plus oral azithromycin, faces mounting resistance concerns and administration barriers (1). Gepotidacin, a first-in-class oral triazaacenaphthyl